Top

BioDrugs

Published in:

01-06-2010 | Review Article

Strategies for In Vivo Delivery of siRNAs

Recent Progress

Authors: Dr Yuriko Higuchi, Shigeru Kawakami, Mitsuru Hashida

Published in: BioDrugs | Issue 3/2010

Abstract

RNA interference (RNAi) is a post-transcriptional gene-silencing mechanism that involves the degradation of messenger RNA in a highly sequence-specific manner. Double-stranded small interfering RNA (siRNA), consisting of 21–25 nucleotides, can induce RNAi and inhibit the expression of target proteins. Therefore, siRNA is considered a promising therapeutic for treatment of a variety of diseases, including genetic and viral diseases, and cancer. Clinical trials of siRNA are ongoing or have been planned, although some issues need to be addressed. For example, cellular uptake of naked siRNA is extremely low due to its polyanionic nature. Furthermore, siRNA is easily degraded by enzymes in blood, tissues, and cells. Several types of chemically modified siRNA have been produced and investigated to improve stability; these have involved modification of the siRNA backbone, the sugar moiety, and the nucleotide bases of antisense and/or sense strands. Because the accumulation at the target site after administration is extremely low, even if stability is improved, an effective delivery system is required to induce RNAi at the site of action. Delivery strategies can be categorized into physical methods, conjugation methods, and drug delivery system carrier-mediated methods. Physical techniques can enhance siRNA uptake at a specific tissue site using electroporation, pressure, mechanical massage, etc. Terminal modification of siRNAs can enhance their resistance to degradation by exonucleases in serum and tissue. Moreover, modification with a suitable ligand can achieve targeted delivery. Several types of carrier for drug delivery have been developed for siRNA in addition to traditional cationic liposome and cationic polymer systems. Ultrasound and microbubbles or liposomal bubbles have also been used in combination with a carrier for siRNA delivery. New materials with unique characteristics such as carbon nanotubes, gold nanoparticles, and gold nanorods have attracted attention as innovative carriers for siRNA.

Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998 Feb 19; 391(6669): 806–11PubMedCrossRef

Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001 May 24; 411(6836): 494–8PubMedCrossRef

McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002 Oct; 3(10): 737–47PubMedCrossRef

Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004 Sep 16; 431(7006): 371–8PubMedCrossRef

Caplen NJ, Parrish S, Imani F, et al. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci U S A 2001 Aug 14; 98(17): 9742–7PubMedCrossRef

Takakura Y, Hashida M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm Res 1996 Jun; 13(6): 820–31PubMedCrossRef

Higuchi Y, Kawakami S, Yamashita F, et al. The potential role of fucosylated cationic liposome/NFκB decoy complexes in the treatment of cytokine-related liver disease. Biomaterials 2007 Jan; 28(3): 532–9PubMedCrossRef

Higuchi Y, Kawakami S, Oka M, et al. Intravenous administration of man-nosylated cationic liposome/NFκB decoy complexes effectively prevent LPS-induced cytokine production in a murine liver failure model. FEBS Lett 2006 Jun 26; 580(15): 3706–14PubMedCrossRef

Miyao T, Takakura Y, Akiyama T, et al. Stability and pharmacokinetic characteristics of oligonucleotides modified at terminal linkages in mice. Antisense Res Dev 1995 Summer; 5(2): 115–21PubMed

10.

Takakura Y, Mahato RI, Yoshida M, et al. Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Nucleic Acid Drug Dev 1996 Fall; 6(3): 177–83PubMedCrossRef

11.

Sawai K, Miyao T, Takakura Y, et al. Renal disposition characteristics of oligonucleotides modified at terminal linkages in the perfused rat kidney. Antisense Res Dev 1995 Winter; 5(4): 279–87PubMed

12.

Sawai K, Mahato RI, Oka Y, et al. Disposition of oligonucleotides in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake. J Pharmacol Exp Ther 1996 Oct; 279(1): 284–90PubMed

13.

Medarova Z, Pharm W, Farrar C,et al. In vivo imaging ofsiRNA delivery and silencing in tumors. Nat Med 2007 Mar; 13(3): 372–7PubMedCrossRef

14.

Lee JH, Lee K, Moon SH, et al. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed Engl 2009; 48(23): 4174–9PubMedCrossRef

15.

Yezhelyev MV, Qi L, O'Regan RM, et al. Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J Am Chem Soc 2008 Jul 16; 130(28): 9006–12PubMedCrossRef

16.

Qi L, Gao X. Quantum dot-amphipol nanocomplex for intracellular delivery and real-time imaging of siRNA. ACS Nano 2008 Jul; 2(7): 1403–10PubMedCrossRef

17.

Klein S, Zolk O, Fromm MF, et al. Functionalized silicon quantum dots tailored for targeted siRNA delivery. Biochem Biophys Res Commun 2009 Sep 11; 387(1): 164–8PubMedCrossRef

18.

Eder PS, DeVine RJ, Dagle JM, et al. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res Dev 1991 Summer; 1(2): 141–51PubMed

19.

Kennedy S, Wang D, Ruvkun G. A conserved siRNA-degrading RNase negatively regulates RNA interference in C. elegans. Nature 2004 Feb 12; 427(6975): 645–9PubMedCrossRef

20.

Amarzguioui M, Holen T, Babaie E, et al. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 2003 Jan 15; 31(2): 589–95PubMedCrossRef

21.

Bramsen JB, Laursen MB, Damgaard CK, et al. Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res 2007; 35(17): 5886–97PubMedCrossRef

22.

Chiu YL, Rana TM. RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell 2002 Sep; 10(3): 549–61CrossRef

23.

Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA 2006 Jul; 12(7): 1197–205PubMedCrossRef

24.

Bramsen JB, Laursen MB, Nielsen AF, et al. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 2009 May; 37(9): 2867–81PubMedCrossRef

25.

Behlke MA. Chemical modification of siRNAs for in vivo use. Oligonucleotides 2008 Dec; 18(4): 305–19PubMedCrossRef

26.

Braasch DA, Jensen S, Liu Y, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 2003 Jul 8; 42(26): 7967–75PubMedCrossRef

27.

Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA 2003 Sep; 9(9): 1034–48PubMedCrossRef

28.

Li ZY, Mao H, Kallick DA, et al. The effects of thiophosphate substitutions on native siRNA gene silencing. Biochem Biophys Res Commun 2005 Apr 15; 329(3): 1026–30PubMedCrossRef

29.

Choung S, Kim YJ, Kim S, et al. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun 2006 Apr 14; 342(3): 919–27PubMedCrossRef

30.

Hall AH, Wan J, Shaughnessy EE, et al. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res 2004 Nov 15; 32(20): 5991–6000PubMedCrossRef

31.

Hall AH, Wan J, Spesock A, et al. High potency silencing by single-stranded boranophosphate siRNA. Nucleic Acids Res 2006 May 22; 34(9): 2773–81PubMedCrossRef

32.

Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999 Dec 10; 1489(1): 69–84PubMedCrossRef

33.

Braasch DA, Paroo Z, Constantinescu A, et al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 2004 Mar 8; 14(5): 1139–43PubMedCrossRef

34.

Hoerter JA, Walter NG. Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. RNA 2007 Nov; 13(11): 1887–93PubMedCrossRef

35.

Czauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003 Jun 1; 31(11): 2705–16PubMedCrossRef

36.

Allerson CR, Sioufi N, Jarres R, et al. Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem 2005 Feb 24; 48(4): 901–4PubMedCrossRef

37.

Prakash TP, Allerson CR, Dande P, et al. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem 2005 Jun 30; 48(13): 4247–53PubMedCrossRef

38.

Layzer JM, McCaffrey AP, Tanner AK, et al. In vivo activity of nuclease-resistant siRNAs. RNA 2004 May; 10(5): 766–71PubMedCrossRef

39.

Morrissey DV, Blanchard K, Shaw L, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005 Jun; 41(6): 1349–56PubMedCrossRef

40.

Grünweller A, Wyszko E, Bieber B, et al. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 2003 Jun 15; 31(12): 3185–93PubMedCrossRef

41.

Elmén J, Thonberg H, Ljungberg K, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 2005 Jan 14; 33(1): 439–47PubMedCrossRef

42.

Mook OR, Baas F, de Wissel MB, et al. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther 2007 Mar; 6(3): 833–43PubMedCrossRef

43.

Dowler T, Bergeron D, Tedeschi AL, et al. Improvements in siRNA properties mediated by 20-deoxy-2′-fluoro-beta-D-arabinonucleic acid (FANA). Nucleic Acids Res 2006 Mar 22; 34(6): 1669–75PubMedCrossRef

44.

Gao S, Dagnaes-Hansen F, Nielsen EJ, et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 2009 Jul; 17(7): 1225–33PubMedCrossRef

45.

Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999 Jul; 6(7): 1258–66PubMedCrossRef

46.

Zhang G, Budker V, Wolff J. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999 Jul 1; 10(10): 1735–7PubMedCrossRef

47.

Suda T, Suda K, Liu D. Computer-assisted hydrodynamic gene delivery. Mol Ther 2008 Jun; 16(6): 1098–104PubMedCrossRef

48.

Liu F, Huang L. Noninvasive gene delivery to the liver by mechanical massage. Hepatology 2002 Jun; 35(6): 1314–9PubMedCrossRef

49.

Liu F, Lei J, Vollmer R, et al. Mechanism of liver gene transfer by mechanical massage. Mol Ther 2004 Mar; 9(3): 452–7PubMedCrossRef

50.

Mukai H, Kawakami S, Hashida M. Renal press-mediated transfection method for plasmid DNA and siRNA to the kidney. Biochem Biophys Res Commun 2008 Aug 1; 372(3): 383–7PubMedCrossRef

51.

Mukai H, Kawakami S, Kamiya Y, et al. Tissue press-mediated transfection method: transfection to the spleen as a novel target, controlling the tissue press and evaluation of the pro-inflammatory cytokine production. Hum Gene Ther 2009 Oct; 20(10): 1157–67PubMedCrossRef

52.

Coster HG. A quantitative analysis of the voltage-current relationships of fixed charge membranes and the associated property of “punch-through”. Biophys J 1965 Sep; 5(5): 669–86PubMedCrossRef

53.

Kong XC, Barzaghi P, Ruegg MA. Inhibition of synapse assembly in mam-malian muscle in vivo by RNA interference. EMBO Rep 2004 Feb; 5(2): 183–8PubMedCrossRef

54.

Golzio M, Mazzolini L, Moller P, et al. Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery. Gene Ther 2005 Feb; 12(3): 246–51PubMedCrossRef

55.

Matsuda T, Cepko CL. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci U S A 2004 Jan 6; 101(1): 16–22PubMedCrossRef

56.

Schiffelers RM, Xu J, Storm G, et al. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum 2005 Apr; 52(4): 1314–8PubMedCrossRef

57.

Takahashi Y, Nishikawa M, Kobayashi N, et al. Gene silencing in primary and metastatic tumors by small interfering RNA delivery in mice: quantitative analysis using melanoma cells expressing firefly and sea pansy luciferases. J Control Release 2005 Jul 20; 105(3): 332–43PubMedCrossRef

58.

Takei Y, Nemoto T, Mu P, et al. In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency. Mol Cancer Ther 2008 Jan; 7(1): 211–21PubMedCrossRef

59.

Guignet EG, Meyer T. Suspended-drop electroporation for high-throughput delivery of biomolecules into cells. Nat Methods 2008 May; 5(5): 393–5PubMedCrossRef

60.

Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003 Oct 17; 115(2): 209–16PubMedCrossRef

61.

Schwarz DS, Hutvágner G, Du T, et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003 Oct 17; 115(2): 199–208PubMedCrossRef

62.

Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004 Nov 11; 432(7014): 173–8PubMedCrossRef

63.

McNamara 2nd JO, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006 Aug; 24(8): 1005–15PubMedCrossRef

64.

Zhou J, Li H, Li S, et al. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008 Aug; 16(8): 1481–9PubMedCrossRef

65.

Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 2004 Jan 30; 558(1–3): 63–8PubMedCrossRef

66.

Davidson TJ, Harel S, Arboleda VA, et al. Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J Neurosci 2004 Nov 10; 24(45): 10040–6PubMedCrossRef

67.

Moschos SA, Jones SW, Perry MM, et al. Lung delivery studies using siRNA conjugated to TAT(48–60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 2007 Sep–Oct; 18(5): 1450–9PubMedCrossRef

68.

Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986 Dec; 46(12 Pt 1): 6387–92PubMed

69.

Sonoke S, Ueda T, Fujiwara K, et al. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res 2008 Nov 1; 68(21): 8843–51PubMedCrossRef

70.

Kawakami S, Higuchi Y, Hashida M. Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. J Pharm Sci 2008 Feb; 97(2): 726–45PubMedCrossRef

71.

Peer D, Park EJ, Morishita Y, et al. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008 Feb 1; 319(5863): 627–30PubMedCrossRef

72.

Zheng X, Vladau C, Zhang X, et al. A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. Blood 2009 Mar 19; 113(12): 2646–54PubMedCrossRef

73.

Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008 Apr; 26(4): 431–42PubMedCrossRef

74.

Kim SI, Shin D, Choi TH, et al. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther 2007 Jun; 15(6): 1145–52PubMed

75.

Sato A, Takagi M, Shimamoto A, et al. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 2007 Mar; 28(7): 1434–42PubMedCrossRef

76.

Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008 May; 26(5): 561–9PubMedCrossRef

77.

Akinc A, Goldberg M, Qin J, et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 2009 May; 17(5): 872–9PubMedCrossRef

78.

Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005 Aug; 23(8): 1002–7PubMedCrossRef

79.

Judge AD, Robbins M, Tavakoli I, et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009 Mar; 119(3): 661–73PubMedCrossRef

80.

Kinoshita M, Hynynen K. A novel method for the intracellular delivery of siRNA using microbubble-enhanced focused ultrasound. Biochem Biophys Res Commun 2005 Sep 23; 335(2): 393–9PubMedCrossRef

81.

Kinoshita M, Hynynen K. Key factors that affect sonoporation efficiency in in vitro settings: the importance of standing wave in sonoporation. Biochem Biophys Res Commun 2007 Aug 10; 359(4): 860–5PubMedCrossRef

82.

Otani K, Yamahara K, Ohnishi S, et al. Nonviral delivery of siRNA into mesenchymal stem cells by a combination of ultrasound and microbubbles. J Control Release 2009 Jan 19; 133(2): 146–53PubMedCrossRef

83.

Negishi Y, Endo Y, Fukuyama T, et al. Delivery of siRNA into the cytoplasm by liposomal bubbles and ultrasound. J Control Release 2008 Dec 8; 132(2): 124–30PubMedCrossRef

84.

MacDiarmid JA, Mugridge NB, Weiss JC, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 2007 May; 11(5): 431–45PubMedCrossRef

85.

MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat Biotechnol 2009 Jul; 27(7): 643–51PubMedCrossRef

86.

Minakuchi Y, Takeshita F, Kosaka N, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004 Jul 22; 32(13): e109PubMedCrossRef

87.

Takeshita F, Minakuchi Y, Nagahara S, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A 2005 Aug 23; 102(34): 12177–82PubMedCrossRef

88.

Kinouchi N, Ohsawa Y, Ishimaru N, et al. Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. Gene Ther 2008 Aug; 15(15): 1126–30PubMedCrossRef

89.

Howard KA, Paludan SR, Behlke MA, et al. Chitosan/siRNA nanoparticle-mediated TNF-α knockdown in peritoneal macrophages for anti-inflammatory treatment in amurine arthritis model. Mol Ther 2009 Jan; 17(1): 162–8PubMedCrossRef

90.

Kawakami S, Hashida M. Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 2007 Jun; 22(3): 142–51PubMedCrossRef

91.

Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 2007 Mar 30; 59(2–3): 164–82PubMedCrossRef

92.

Gao K, Huang L. Nonviral methods for siRNA delivery. Mol Pharm 2009 May–Jun;6(3): 651–8PubMedCrossRef

93.

Akinc A, Thomas M, Klibanov AM, et al. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med 2005 May; 7(5): 657–63PubMedCrossRef

94.

Saito Y, Higuchi Y, Kawakami S, et al. Immunostimulatory characteristics induced by linear polyethyleneimine/plasmid DNA complexes in cultured macrophages. Hum Gene Ther 2009 Feb; 20(2): 137–45PubMedCrossRef

95.

Kim YH, Park JH, Lee M, et al. Polyethylenimine with acid-labile linkages as a biodegradable gene carrier. J Control Release 2005 Mar 2; 103(1): 209–19PubMedCrossRef

96.

Woodrow KA, Cu Y, Booth CJ, et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009 Jun; 8(6): 526–33PubMedCrossRef

97.

Vandenbroucke RE, De Geest BG, Bonné S, et al. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(beta-amino esters). J Gene Med 2008 Jul; 10(7): 783–94PubMedCrossRef

98.

Aouadi M, Tesz GJ, Nicoloro SM, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009 Apr 30; 458(7242): 1180–4PubMedCrossRef

99.

Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009 May–Jun; 6(3): 659–68PubMedCrossRef

100.

Eguchi A, Meade BR, Chang YC, et al. Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 2009 Jun; 27(6): 567–71PubMedCrossRef

101.

Crombez L, Aldrian-Herrada G, Konate K, et al. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 2009 Jan; 17(1): 95–103PubMedCrossRef

102.

Crombez L, Morris MC, Dufort S, et al. Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res 2009 Aug; 37(14): 4559–69PubMedCrossRef

103.

Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007 Jul 5; 448(7149): 39–43PubMedCrossRef

104.

Kumar P, Ban HS, Kim SS, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008 Aug 22; 134(4): 577–86PubMedCrossRef

105.

Kam NW, Liu Z, Dai H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc 2005 Sep 14; 127(36): 12492–3PubMedCrossRef

106.

Liu Z, Winters M, Holodniy M, et al. siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem Int Ed Engl 2007; 46(12): 2023–7PubMedCrossRef

107.

Wang X, Ren J, Qu X. Targeted RNA interference of cyclin A2 mediated by functionalized single-walled carbon nanotubes induces proliferation arrest and apoptosis in chronic myelogenous leukemia K562 cells. Chem Med Chem 2008 Jun; 3(6): 940–5PubMed

108.

Zhang Z, Yang X, Zhang Y, et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res 2006 Aug 15

109.

Podesta JE, Al-Jamal KT, Herrero MA, et al. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 2009 May; 5(10): 1176–85PubMedCrossRef

110.

Herrero MA, Toma FM, Al-Jamal KT, et al. Synthesis and characterization of a carbon nanotube-dendron series for efficient siRNA delivery. J Am Chem Soc 2009 Jul 22; 131(28): 9843–8PubMedCrossRef

111.

Bonoiu AC, Mahajan SD, Ding H, et al. Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci U S A 2009 Apr 7; 106(14): 5546–50PubMedCrossRef

112.

Elbakry A, Zaky A, Liebl R, et al. Layer-by-layer assembled gold nanoparticles for siRNA delivery. Nano Lett 2009 May; 9(5): 2059–64PubMedCrossRef

113.

Giljohann DA, Seferos DS, Prigodich AE, et al. Gene regulation with polyvalent siRNA-nanoparticle conjugates. J Am Chem Soc 2009 Feb 18; 131(6): 2072–3PubMedCrossRef

114.

Lee JS, Green JJ, Love KT, et al. Gold, poly(beta-amino ester) nanoparticles for small interfering RNA delivery. Nano Lett 2009 Jun; 9(6): 2402–6PubMedCrossRef

115.

Braun GB, Pallaoro A, Wu G, et al. Laser-activated gene silencing via gold nanoshell-siRNA conjugates. ACS Nano. Epub 2009 Jun 15

Title: Strategies for In Vivo Delivery of siRNAs
Recent Progress
Authors: Dr Yuriko Higuchi
Shigeru Kawakami
Mitsuru Hashida
Publication date: 01-06-2010
Publisher: Springer International Publishing
Published in: BioDrugs / Issue 3/2010
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI: https://doi.org/10.2165/11534450-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Strategies for In Vivo Delivery of siRNAs

Recent Progress

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Re-Engineering Clostridial Neurotoxins for the Treatment of Chronic Pain

The Emerging Role of MicroRNAs as a Therapeutic Target for Cardiovascular Disease

Technosphere® Insulin

Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration

Dasatinib

Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)- Positive Early Breast Cancer